Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Inclusion Criteria:

Provide written informed consent
Histologically confirmed cancers for which no curative therapy exists
Documented HER2 or EGFR exon 18 mutation
Participants must agree and commit to use appropriate methods of contraception as outlined in the protocol
At least one measurable lesion, defined by RECIST v1.1

Exclusion Criteria:

Participants harboring ineligible somatic HER2 mutations
Prior treatment with any HER2-directed tyrosine kinase inhibitor (e.g., lapatinib, afatinib, dacomitinib, neratinib) is excluded with the following exception: patients with EGFR exon 18 mutated NSCLC who may have received afatinib, osimertinib, or other pan HER or EGFR TKIs remain eligible
Participants who are receiving any other anticancer agents
Symptomatic or unstable brain metastases
Women who are pregnant or breast-feeding

There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.